Radiology and Nuclear Medicine Department, School of Paramedical Sciences, Kermanshah University of Medical Sciences, Kermanshah, Iran.
Department of Toxicology and Pharmacology, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
Life Sci. 2020 Jan 15;241:117173. doi: 10.1016/j.lfs.2019.117173. Epub 2019 Dec 13.
Doxorubicin, as an effective chemotherapeutic drug, is commonly used for combating various solid and hematological tumors. However, doxorubicin-induced cardiotoxicity is considered as a serious adverse effect, and it limits the clinical use of this chemotherapeutic drug. The use of melatonin can lead to a decrease in the cardiotoxic effect induced by doxorubicin. The aim of this review was to evaluate the potential role of melatonin in the prevention of doxorubicin-induced cardiotoxicity.
This review was conducted by a full systematic search strategy based on PRISMA guidelines for the identification of relevant literature in the electronic databases of PubMed, Web of Science, Embase, and Scopus up to January 2019 using search terms in the titles and abstracts. 286 articles were screened in accordance with our inclusion and exclusion criteria. Finally, 28 articles were selected in this systematic review.
The findings demonstrated that doxorubicin-treated groups had increased mortality, decreased body weight and heart weight, and increased ascites compared to the control groups; the co-administration of melatonin revealed an opposite pattern compared to the doxorubicin-treated groups. Also, this chemotherapeutic agent can lead to biochemical and histopathological changes; as for most of the cases, these alterations were reversed near to normal levels (control groups) by melatonin co-administration. Melatonin exerts these protection effects through mechanisms of anti-oxidant, anti-apoptosis, anti-inflammatory, and mitochondrial function.
The results of this systematic review indicated that co-administration of melatonin ameliorates the doxorubicin-induced cardiotoxicity.
多柔比星作为一种有效的化疗药物，常用于治疗各种实体瘤和血液系统肿瘤。然而，多柔比星引起的心脏毒性被认为是一种严重的不良反应，限制了这种化疗药物的临床应用。褪黑素的使用可以降低多柔比星引起的心脏毒性。本综述的目的是评估褪黑素在预防多柔比星引起的心脏毒性中的潜在作用。
本综述按照 PRISMA 指南进行了全面的系统搜索策略，使用标题和摘要中的检索词，在电子数据库 PubMed、Web of Science、Embase 和 Scopus 中检索了截至 2019 年 1 月的相关文献。根据我们的纳入和排除标准，筛选了 286 篇文章。最后，本系统综述选择了 28 篇文章。
研究结果表明，与对照组相比，多柔比星处理组的死亡率增加，体重和心脏重量降低，腹水增加；与多柔比星处理组相比，褪黑素联合使用呈现出相反的模式。此外，这种化疗药物会导致生化和组织病理学变化；在大多数情况下，这些变化通过褪黑素联合使用可以恢复到接近正常水平（对照组）。褪黑素通过抗氧化、抗凋亡、抗炎和线粒体功能等机制发挥这些保护作用。
本系统综述的结果表明，褪黑素联合使用可以改善多柔比星引起的心脏毒性。
